subject area of

• A Phase I Biodistribution and Pharmacokinetic Trial of Humanized Monoclonal Antibody Hu3s193 in Patients with Advanced Epithelial Cancers that Express the Lewis-Y Antigen  Academic Article
• A Phase I/II Study of Erlotinib in Combination with the Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody IMC-A12 (Cixutumumab) in Patients with Advanced Non-small Cell Lung Cancer  Academic Article
• A Possible Role for Metallic Ions in the Carbohydrate Cluster Recognition Displayed by a Lewis Y Specific Antibody  Academic Article
• A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer  Academic Article
• A phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer  Academic Article
• A phase II trial with anti-Lewis-Y monoclonal antibody (hu3S193) for the treatment of platinum resistant/refractory ovarian, fallopian tube and primary peritoneal carcinoma  Conference Paper
• A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors  Academic Article
• ASPECCT: panitumumab versus cetuximab for colorectal cancer  Letter
• Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity  Academic Article
• Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): A case report and review of the literature  Academic Article
• Association of good oncological response to therapy with the development of rheumatic immune-related adverse events following PD-1 inhibitor therapy  Academic Article
• Cardiotoxicity in Patients Treated With Bevacizumab Is Potentially Reversible  Academic Article
• Cell death in chronic inflammation: breaking the cycle to treat rheumatic disease  Academic Article
• Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate  Academic Article
• Characterization of ABT-806, a humanized tumor-specific anti-EGFR monoclonal antibody  Academic Article
• Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials  Academic Article
• Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer  Academic Article
• Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial  Academic Article
• Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: The AGITG ATTAX2 trial  Academic Article
• Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer  Academic Article
• Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.  Academic Article
• Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases  Academic Article
• Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study  Academic Article
• Evolution of anti-HER2 therapies for cancer treatment  Academic Article
• Hallmarks of response to immune checkpoint blockade  Academic Article
• IL-1 beta and IL-18: inflammatory markers or mediators of hypertension?  Academic Article
• Immunological effects of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma  Academic Article
• Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer  Conference Paper
• Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma  Academic Article
• Molecular Imaging and Quantitation of EphA2 Expression in Xenograft Models with Zr-89-DS-8895a  Academic Article
• Molecular imaging of T cell co-regulator factor B7-H3 with Zr-89-DS-5573a  Academic Article
• Molecular imaging of death receptor 5 occupancy and saturation kinetics in vivo by humanized monoclonal antibody CS-1008  Academic Article
• Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy  Academic Article
• PIK3CA Mutation/PTEN Expression Status Predicts Response of Colon Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Cetuximab  Academic Article
• PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer  Academic Article
• Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma  Academic Article
• Phase I Biodistribution and Pharmacokinetic Study of Lewis Y-Targeting Immunoconjugate CMD-193 in Patients with Advanced Epithelial Cancers  Academic Article
• Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer  Academic Article
• Population Pharmacokinetics of Sibrotuzumab, A Novel Therapeutic Monoclonal Antibody, in Cancer Patients  Academic Article
• Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab*  Academic Article
• Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial  Academic Article
• Safety, pharmacokinetic and dosimetry evaluation of the proposed thrombus imaging agent 99mTc-DI-DD-3B6/22-80B3 Fab′  Academic Article
• Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma  Academic Article
• Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029) : an open-label, phase 1b trial  Academic Article
• Targeted chemoradiation in metastatic colorectal cancer: A phase i trial of 131i-hua33 with concurrent capecitabine  Academic Article
• Targeting Lewis Y (Ley) in Small Cell Lung Cancer with a Humanized Monoclonal Antibody, hu3S193: A Pilot Trial Testing Two Dose Levels  Academic Article
• Telomere length is a novel predictive biomarker of sensitivity to anti-EGFR therapy in metastatic colorectal cancer  Academic Article
• The Plasticity of Oncogene Addiction: Implications for Targeted Therapies Directed to Receptor Tyrosine Kinases  Academic Article
• Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant–dependent lung carcinomas  Academic Article
• Therapeutic efficacy of177Lu-CHX-A″-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy  Academic Article
• Tumor Targeting by a Multivalent Single-Chain Fv (scFv) Anti-Lewis Y Antibody Construct  Academic Article
• Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer  Academic Article